Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial

Laurence Klotz, Abdenour Nabid, Celestia Higano, Christopher Ryan, Marlene Kebabdjian, Joseph Chin

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Introduction: We studied the effect of dutasteride on the length of the off-treatment period in prostate cancer patients on intermittent androgen deprivation (IAD) therapy.

    Methods: We conducted a randomized, placebo-controlled Phase II trial in men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. Patients were randomized to dutasteride (0.5 mg/day) or placebo. All patients received androgen deprivation therapy (ADT), which was stopped at month 9 if the PSA level was

    Results: There were 87 evaluable patients: 49 dutasteride, 38 placebo. In total, 80 patients completed one treatment cycle: 45 dutasteride, 35 placebo. The median time off treatment for patients reaching ≥5 ng/mL was 18.6 and 16.7 months for dutasteride and placebo, respectively (p = 0.7600). The median PSA nadir at 9 months was 0.1 and 0.075 ng/mL, respectively (p = 0.4486). There were no cases of androgen-independent prostate cancer. Our study limitations include its short duration with only one treatment cycle evaluated.

    Conclusions: This small-scale Phase II randomized controlled trial showed no benefit to the addition of dutasteride to an IAD regimen.

    Original languageEnglish (US)
    Pages (from-to)e789-e794
    JournalJournal of the Canadian Urological Association
    Volume8
    Issue number11-12
    DOIs
    StatePublished - Nov 1 2014

    Fingerprint

    Androgens
    Placebos
    Prostate-Specific Antigen
    Prostatic Neoplasms
    Therapeutics
    Dutasteride
    Randomized Controlled Trials

    Keywords

    • 5 ARI
    • Intermittent androgen deprivation
    • Prostate cancer

    ASJC Scopus subject areas

    • Oncology
    • Urology

    Cite this

    Effect of dutasteride in men receiving intermittent androgen ablation therapy : The AVIAS trial. / Klotz, Laurence; Nabid, Abdenour; Higano, Celestia; Ryan, Christopher; Kebabdjian, Marlene; Chin, Joseph.

    In: Journal of the Canadian Urological Association, Vol. 8, No. 11-12, 01.11.2014, p. e789-e794.

    Research output: Contribution to journalArticle

    Klotz, Laurence ; Nabid, Abdenour ; Higano, Celestia ; Ryan, Christopher ; Kebabdjian, Marlene ; Chin, Joseph. / Effect of dutasteride in men receiving intermittent androgen ablation therapy : The AVIAS trial. In: Journal of the Canadian Urological Association. 2014 ; Vol. 8, No. 11-12. pp. e789-e794.
    @article{4b96d8fda24948db9f7c8c225c66e585,
    title = "Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial",
    abstract = "Introduction: We studied the effect of dutasteride on the length of the off-treatment period in prostate cancer patients on intermittent androgen deprivation (IAD) therapy.Methods: We conducted a randomized, placebo-controlled Phase II trial in men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. Patients were randomized to dutasteride (0.5 mg/day) or placebo. All patients received androgen deprivation therapy (ADT), which was stopped at month 9 if the PSA level was Results: There were 87 evaluable patients: 49 dutasteride, 38 placebo. In total, 80 patients completed one treatment cycle: 45 dutasteride, 35 placebo. The median time off treatment for patients reaching ≥5 ng/mL was 18.6 and 16.7 months for dutasteride and placebo, respectively (p = 0.7600). The median PSA nadir at 9 months was 0.1 and 0.075 ng/mL, respectively (p = 0.4486). There were no cases of androgen-independent prostate cancer. Our study limitations include its short duration with only one treatment cycle evaluated.Conclusions: This small-scale Phase II randomized controlled trial showed no benefit to the addition of dutasteride to an IAD regimen.",
    keywords = "5 ARI, Intermittent androgen deprivation, Prostate cancer",
    author = "Laurence Klotz and Abdenour Nabid and Celestia Higano and Christopher Ryan and Marlene Kebabdjian and Joseph Chin",
    year = "2014",
    month = "11",
    day = "1",
    doi = "10.5489/cuaj.2332",
    language = "English (US)",
    volume = "8",
    pages = "e789--e794",
    journal = "Journal of the Canadian Urological Association",
    issn = "1911-6470",
    publisher = "Canadian Medical Association",
    number = "11-12",

    }

    TY - JOUR

    T1 - Effect of dutasteride in men receiving intermittent androgen ablation therapy

    T2 - The AVIAS trial

    AU - Klotz, Laurence

    AU - Nabid, Abdenour

    AU - Higano, Celestia

    AU - Ryan, Christopher

    AU - Kebabdjian, Marlene

    AU - Chin, Joseph

    PY - 2014/11/1

    Y1 - 2014/11/1

    N2 - Introduction: We studied the effect of dutasteride on the length of the off-treatment period in prostate cancer patients on intermittent androgen deprivation (IAD) therapy.Methods: We conducted a randomized, placebo-controlled Phase II trial in men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. Patients were randomized to dutasteride (0.5 mg/day) or placebo. All patients received androgen deprivation therapy (ADT), which was stopped at month 9 if the PSA level was Results: There were 87 evaluable patients: 49 dutasteride, 38 placebo. In total, 80 patients completed one treatment cycle: 45 dutasteride, 35 placebo. The median time off treatment for patients reaching ≥5 ng/mL was 18.6 and 16.7 months for dutasteride and placebo, respectively (p = 0.7600). The median PSA nadir at 9 months was 0.1 and 0.075 ng/mL, respectively (p = 0.4486). There were no cases of androgen-independent prostate cancer. Our study limitations include its short duration with only one treatment cycle evaluated.Conclusions: This small-scale Phase II randomized controlled trial showed no benefit to the addition of dutasteride to an IAD regimen.

    AB - Introduction: We studied the effect of dutasteride on the length of the off-treatment period in prostate cancer patients on intermittent androgen deprivation (IAD) therapy.Methods: We conducted a randomized, placebo-controlled Phase II trial in men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. Patients were randomized to dutasteride (0.5 mg/day) or placebo. All patients received androgen deprivation therapy (ADT), which was stopped at month 9 if the PSA level was Results: There were 87 evaluable patients: 49 dutasteride, 38 placebo. In total, 80 patients completed one treatment cycle: 45 dutasteride, 35 placebo. The median time off treatment for patients reaching ≥5 ng/mL was 18.6 and 16.7 months for dutasteride and placebo, respectively (p = 0.7600). The median PSA nadir at 9 months was 0.1 and 0.075 ng/mL, respectively (p = 0.4486). There were no cases of androgen-independent prostate cancer. Our study limitations include its short duration with only one treatment cycle evaluated.Conclusions: This small-scale Phase II randomized controlled trial showed no benefit to the addition of dutasteride to an IAD regimen.

    KW - 5 ARI

    KW - Intermittent androgen deprivation

    KW - Prostate cancer

    UR - http://www.scopus.com/inward/record.url?scp=84912526351&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84912526351&partnerID=8YFLogxK

    U2 - 10.5489/cuaj.2332

    DO - 10.5489/cuaj.2332

    M3 - Article

    AN - SCOPUS:84912526351

    VL - 8

    SP - e789-e794

    JO - Journal of the Canadian Urological Association

    JF - Journal of the Canadian Urological Association

    SN - 1911-6470

    IS - 11-12

    ER -